On 31 August 2026, KERA and Texas Public Radio ran an interview with Austin oncologist Dr Debra Patt about a blood test that can flag breast cancer coming back months before a scan picks it up. The research behind the story had landed in JAMA Oncology a few weeks earlier, and one number travelled with it: 7.9 months, the average head start the test gave over standard follow-up.
This is not an introduction to the disease — our guide to 乳がん already covers that ground. It answers the question the headline raises for anyone who has finished treatment and is now living in follow-up: can a blood test tell you whether your cancer is returning, and can you ask for one?
What the study actually tested
Researchers at the Institute of Cancer Research in London went back to blood samples collected during c-TRAK TN, a trial that followed 159 women with early triple negative breast cancer judged to be at moderate to high risk of recurrence. Over 1,026 plasma samples were drawn every three months for up to two years after adjuvant treatment finished.
The test looks for circulating tumour DNA, usually shortened to ctDNA: tiny fragments shed by cancer cells into the bloodstream. Finding them after treatment is called molecular residual disease — cancer that no scan can see, because there is not enough of it to make a shadow.
Two findings mattered. First, ctDNA turning up during surveillance was very strongly linked to the cancer returning; in this group the risk difference between women with a positive result and those without was among the largest reported for any blood marker. Second, the newer “tissue-free” version of the test performed as well as the older, personalised kind.
That second point is the practical one. Until now, these tests have been bespoke: the laboratory sequences the original tumour, then builds a blood test tailored to that person’s mutations. It works, but it needs enough stored tumour tissue, and sometimes there is none left after the first round of diagnostic testing. The tissue-free version reads chemical marks on the DNA itself rather than a personal mutation list, so it can be run on anyone.
Why your routine blood panel cannot do this
Here is the part that matters when you are looking at your own results. Nothing on an ordinary blood report detects a returning cancer. The lines you can read tell you about anaemia, liver, kidneys and inflammation — not about tumour DNA.
| 検査 | 何を調べるか | Role in breast cancer follow-up |
|---|---|---|
| 血球算定検査（CBC） | 赤血球・白血球・血小板 | Monitors treatment effects, not recurrence |
| 肝機能検査 | ALT, AST, ALP, bilirubin | Ordered if symptoms suggest a problem, not routinely |
| CA 15-3, CEA | Proteins shed by some breast tumours | Not recommended for routine surveillance after early breast cancer |
| ctDNA / molecular residual disease | Tumour DNA fragments in plasma | Research and specialist use; not a guideline-based test |
CA 15-3 is the one people ask about most, because it is the classic breast tumour marker and it is easy to order. It is genuinely useful for tracking treatment response in metastatic disease. It is not useful for watching a woman in remission who has no symptoms, because levels do not rise in everyone, and testing has never been shown to help people live longer. Our page on 腫瘍マーカー sets out where each one does and does not belong, and if the vocabulary on your report is the obstacle, our guide to 血液検査結果の読み方 starts from scratch.
Detected earlier is not the same as treated better
Dr Patt made the caveat plainly in the KERA interview, and it is the single most important sentence in the whole story. These tests detect recurrence earlier. They have not yet been shown to help anyone live longer because of it.
That gap is not a technicality. Finding cancer sooner only helps if there is something useful to do with the information at that moment, and for molecular residual disease that question is still open. Trials are running now to test whether changing treatment on a positive ctDNA result improves outcomes.
Because the test is not guideline-based, two practical consequences follow. Insurance often does not cover it. And the decision to test at all is a conversation to have with your oncologist before the first sample, not after a result arrives — including what you would both do with a positive one. The same caution is being applied to the wider family of 複数がん早期発見検査 now being evaluated.
最新の科学的進歩をわかりやすく
Searching the literature indexed in PubMed and in the Consensus database over the past three years puts the August headline in context in four ways.
First, the prognostic signal is real and it is large. A meta-analysis pooling 57 studies and more than 5,700 women with operable breast cancer found that detecting ctDNA during follow-up was associated with a much shorter time to relapse, and a 2026 meta-analysis of eighteen prospective studies reached the same conclusion. What that means for you: a positive result is not a vague worry, it is a strong signal. It also means a test with that much weight should not be run casually.
Second, the lead time is consistent. Across studies the average gap between a positive blood test and a visible recurrence lands somewhere between roughly eight and thirteen months, with a wide spread around it. Some women are flagged a few weeks ahead, some more than four years ahead.
Third, and this is the honest limit, a 2026 review in JAMA Oncology by a Dana-Farber team concluded that while these assays are analytically sound and clearly prognostic, their clinical utility has not been demonstrated. Nobody yet knows how often to test, when to start, or which assay to prefer. A separate 2026 review put numbers on why: tumours shed DNA at very different rates, and in some women there is simply too little in the blood for any assay to find.
Fourth, the field is moving toward tests that do not need tumour tissue. The London study is one example; a 2025 US trial of a tissue-free assay in triple negative disease reported similar behaviour, with very few false positives. What that means for you is access rather than accuracy — the same information, available to people whose original biopsy is long gone.
What this changes for you right now
If you are in follow-up after early breast cancer, nothing about your schedule changes today. Follow-up rests on clinical examination and annual imaging, and blood tests are ordered when a symptom or an examination finding calls for them, not on a calendar.
If you are considering a ctDNA test privately, ask three questions before you agree: what happens if it is positive, what happens if it is negative, and who pays. A negative result does not mean the cancer is gone — some tumours shed too little DNA to be seen. A positive result, at present, mostly buys earlier knowledge rather than earlier action.
And if you are reading a report full of numbers you did not expect, remember what those numbers are for. A raised liver enzyme on your 肝機能検査 or an unexpected line on your 血液一般検査（血算） is a reason to ask a question, not a verdict on your cancer. The same logic applies across oncology, whether the subject is the blood test for colon cancerの役割、 lung cancer blood testの役割、 newly approved pancreatic cancer testの役割、 stool test for colorectal screening, or the 2026 data on GLP-1 drugs and breast cancer.
よくある質問
Can I ask my doctor for a ctDNA test after breast cancer?
You can ask, and in some centres you can have one, but it is not part of standard follow-up anywhere. Because it is not guideline-based, insurers frequently decline to cover it, and your oncologist will want to agree with you in advance what a positive result would lead to.
Is CA 15-3 useful for detecting a recurrence?
Not for routine surveillance in someone without symptoms. Levels do not rise in every woman with recurrent disease, and testing has not been shown to improve survival. CA 15-3 has a clearer role in tracking treatment response once metastatic disease is established.
How much earlier does a ctDNA test find a recurrence?
In the London study the average was 7.9 months ahead of standard scans. Pooled figures across many studies cluster around ten to thirteen months, but the range is very wide and averages hide individual variation.
Does a negative ctDNA result mean I am cured?
No. Some tumours release very little DNA into the blood, so a negative result can occur alongside disease that is present. It lowers the probability of recurrence, it does not exclude it.
Which blood tests are part of normal breast cancer follow-up?
None on a routine schedule for most people treated for early breast cancer. Blood tests and scans are done when symptoms or an examination finding suggest a reason, because routine testing has not been shown to help people live longer.
用語集
- Circulating tumour DNA (ctDNA): fragments of DNA released by cancer cells into the bloodstream.
- Liquid biopsy: any test that looks for cancer material in blood rather than in a tissue sample.
- Molecular residual disease (MRD): cancer detectable only at the molecular level, below the threshold of imaging.
- Tumour-informed assay: a blood test built from the mutations found in that person’s own tumour tissue.
- Tissue-free assay: a blood test that reads chemical marks on DNA, needing no tumour sample.
- Triple negative breast cancer: a subtype lacking oestrogen, progesterone and HER2 receptors, more likely to return early.
- Adjuvant therapy: treatment given after surgery to reduce the chance of the cancer returning.
- Lead time: the interval between a test turning positive and the disease becoming detectable by usual means.
- CA 15-3: a protein used as a breast tumour marker, mainly in metastatic disease.
- Recurrence-free survival: the time from treatment until the cancer returns or the person dies.
自分の検査結果を理解する
Most of the blood work done after cancer treatment is not looking for cancer at all — it is checking that your liver, kidneys, blood counts and thyroid have come through the treatment intact. Those results arrive as a wall of abbreviations and reference ranges that explain nothing about your own situation. AI DiagMe reads your entire lab report and tells you, line by line, what each result means for you. Upload your report at aidiagme.com 次の受診前に、わかりやすい解説をご確認ください。
関連記事
- Breast Cancer: Symptoms, Diagnosis and Treatment
- Tumor Markers Explained: What They Can and Cannot Tell You
- Multi-Cancer Early Detection Tests: Where the Evidence Stands
- 血液検査の結果の読み方
- Colon Cancer Blood Test: What It Detects
参考文献
- Texas Public Radio / KERA News. New study finds a blood test may detect recurring breast cancer faster than a scan. 31 August 2026. tpr.org
- The Institute of Cancer Research, London. New, cheaper blood test could help detect breast cancer recurrence earlier. August 2026. icr.ac.uk
- Oncology Central. New tissue-free blood test could detect breast cancer recurrence months before scans. 25 August 2026. oncology-central.com
- Cunningham N, Cutts RJ, Swift C, et al. Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer. JAMA Oncology. 13 August 2026. doi.org （PubMed）
- Schlam I, Tolaney SM, Lin NU, Parsons H, Morganti S. Circulating Tumor DNA in Early Breast Cancer: A Review. JAMA Oncology. 2026;12(7):773-784. doi.org （PubMed）
- Di Cosimo S, Appierto V, Reduzzi C, et al. Circulating tumor DNA in early breast cancer: evidence, challenges, next steps. Cancer. 2026;132(14):e70521. doi.org （PubMed）
- Ademuyiwa FO, Ma CX, Weilbaecher K, et al. Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research. 2025;31(11):2173-2182. doi.org （PubMed）
- Mouabbi JA, Lipsyc-Sharf MD, Yan F. Molecular residual disease testing: advancing clinical decision-making in breast cancer. Clinical Advances in Hematology and Oncology. 2026;24(4 Suppl 4):1-16. pubmed.ncbi.nlm.nih.gov （PubMed）
- Nader-Marta G, et al. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis. ESMO Open. 2024. 参考文献 (Consensus)
- Sisca L, et al. Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment. 2026. 参考文献 (Consensus)
- Nguyen ST, et al. Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer. npj Breast Cancer. 2025. 参考文献 (Consensus)
- American Cancer Society. Follow-up Care After Breast Cancer Treatment. cancer.org
- National Cancer Institute. Tumor Markers. cancer.gov
- MedlinePlus, National Library of Medicine. Tumor Marker Tests. medlineplus.gov
